| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT02503722 Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal… |
date change Primary completion pushed: 2026-06-05 -> 2027-02-28 |
| 2026-06-12 | NCT02503722 Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal… |
date change Completion pushed: 2026-06-05 -> 2027-02-28 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT03047213 | Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With… | Locally Advanced Bladder Urothelial Carcinoma | Active, Not Recruiting |
| NCT06385496 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic… | Advanced Lymphoma | Active, Not Recruiting |
| NCT06390865 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2… | Advanced Lymphoma | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07558733 | Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2… | HR+ HER2- Breast Cancer | Recruiting |
| NCT06811116 | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy… | Advanced Hepatocellular Carcinoma | Recruiting |
| Phase 1 | |||
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent… | Adult Glioblastoma | Active, Not Recruiting |
| NCT04250545 | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in… | Leptomeningeal Neoplasm | Active, Not Recruiting |
| NCT02503722 | Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal… | Metastatic Lung Non-Small Cell Carcinoma | Active, Not Recruiting |